Pharmacy Benefit Management

From Drug Benefit News - Nearly a year after the last of the valid patents on Teva Pharmaceutical Industries Ltd.’s multiple sclerosis drug Copaxone (glatiramer acetate) expired, the FDA on April 16 cleared Sandoz Inc. and Momenta Pharmaceuticals, Inc. to market Glatopa, the first substitutable generic version of the daily injectable therapy. While entry of the generic has the potential to significantly lower costs in the multiple sclerosis category, there are several uncertainties that may impede successful penetration of the market, say industry insiders. Read more

From Specialty Pharmacy News - A confluence of events within the health care industry in 2014 — many of them tied to specialty medications — made it an exceptional year in many ways. Read more

Pharmacy Benefit Management Blog

By Angela Maas - May 18, 2015
It should come as really no surprise that the multiple sclerosis (MS) category is a tremendous driver of specialty drug costs for health plans. After all, that therapeutic class consistently ranks in the top three specialty categories — along with inflammatory conditions and cancer — among PBMs’...
By Lauren Flynn Kelly - May 7, 2015
A new report from the HHS Office of Inspector General (OIG) found that the total amount of rebates paid by pharmaceutical manufacturers for brand-name prescription drugs covered by Medicaid in 2012 far exceeded the amount of rebates captured under the Medicare Part D program during that time....
By Lauren Flynn Kelly - April 2, 2015
Trend report season is upon us. It’s that time of year when PBMs reveal exactly what ate away at their clients’ drug spending in the most recent calendar year, and each does so with its own spin or news angle. In a new report from Prime Therapeutics LLC, the Blues plan-owned PBM examines the first...

It's quick and easy to sign up for FREE access to!

Why do I need to register?